Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8256335 | 1.00 | HDAC1 (0.36) | HDAC1PPARAPPARGCASRGRN | |
| SCHEMBL5870354 | 0.82 | GRN (0.40) | HDAC1GRNSORT1 | |
| SCHEMBL8431108 | 0.82 | GRN (0.40) | HDAC1GRNSORT1 | |
| SCHEMBL5870192 | 0.76 | HDAC1 (0.36) | HDAC1PPARAPPARGHCRTR1HCRTR2 | |
| SCHEMBL5869738 | 0.76 | P2RX7 (0.39) | P2RX7HCRTR1HCRTR2 | |
| SCHEMBL5869731 | 0.76 | P2RX7 (0.39) | P2RX7HCRTR1HCRTR2 | |
| SCHEMBL5870220 | 0.75 | ACE2 (0.49) | HDAC1PPARAPPARGGRNSORT1 | |
| SCHEMBL5869937 | 0.75 | ACE2 (0.49) | HDAC1PPARAPPARGGRNSORT1 | |
| SCHEMBL5869941 | 0.75 | ACE2 (0.49) | HDAC1PPARAPPARGGRNSORT1 | |
| SCHEMBL8249930 | 0.75 | ACE2 (0.49) | HDAC1PPARAPPARGGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | HDAC1 236/4885PPARA 540/4885PPARG 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.